Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | CHUK | O15111 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.36 |
| ▸ | TAB1 | Q15750 | 2/20 | 0.36 |
| ▸ | AKT1 | P31749 | 4/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | DPYD | Q12882 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL154683 | 0.82 | CHUK (0.61) | CHEK1CHUKLRRK2MAP3K7TAB1 | |
| SCHEMBL5522171 | 0.80 | LRRK2 (0.40) | CHEK1CHUKLRRK2JAK3MAP3K7 | |
| SCHEMBL312426 | 0.79 | CHEK1 (0.49) | CHEK1CHUKLRRK2JAK3MAP3K7 | |
| SCHEMBL9254230 | 0.79 | JAK3 (0.39) | CHEK1CHUKLRRK2JAK3MAP3K7 | |
| SCHEMBL1735020 | 0.77 | CHEK1 (0.50) | CHEK1CHUKLRRK2MAP3K7TAB1 | |
| SCHEMBL31329069 | 0.75 | CHEK1 (0.66) | CHEK1LRRK2JAK3AKT1NOTUM | |
| SCHEMBL1598149 | 0.75 | CHEK1 (0.66) | CHEK1LRRK2JAK3AKT1NOTUM | |
| SCHEMBL5522262 | 0.74 | CHEK1 (0.47) | CHEK1CHUKLRRK2 | |
| SCHEMBL311539 | 0.73 | CHEK1 (0.46) | CHEK1CHUKLRRK2MAP3K7TAB1 | |
| SCHEMBL2323682 | 0.73 | CHEK1 (0.63) | CHEK1CHUKLRRK2JAK3AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169918-B2 | Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-30 | — | — | US | claimed |
| EP-1682564-A1 | METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D|PYRIMIDINE DERIVATIVES | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-26 | — | — | EP | claimed |
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. | 2005-09-29 | — | — | US | claimed |
| WO-2005044835-A1 | METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | GENELABS TECHNOLOGIES, INC. (US) | 2005-05-19 | — | — | WO | claimed |
| CN-101600726-B | Novel nucleoside analogs for treatment of viral infections | NOVARTIS AG CH | 2013-03-27 | — | — | CN | disclosed |
| US-8278282-B2 | Nucleoside analogs for treatment of viral infections | NOVARTIS AG (CH) | 2012-10-02 | — | — | US | disclosed |
| EP-2132216-B1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS PHARMA AG (CH) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011131167-A2 | BISTABLE MAGNETIC ACTUATOR | JOHNSON ELECTRIC DRESDEN GMBH (DE) | 2011-10-27 | — | — | WO | disclosed |
| US-20100227833-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS PHARMA AG (CH) | 2010-09-09 | — | — | US | disclosed |
| US-20100144655-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
| WO-2010015643-A1 | NEW ANTIVIRAL MODIFIED NUCLEOSIDES | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| EP-2132216-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | Novartis Pharma AG. (CH) | 2009-12-16 | — | — | EP | disclosed |
| CN-101600726-A | The novel nucleoside analogs that is used for the treatment of virus infection | NOVARTIS AG (CH) | 2009-12-09 | — | — | CN | disclosed |
| WO-2008095993-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| US-7169918-B2 | Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227833-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | MAVS, HAVCR2, SAMHD1 | CHEK1 2223/4885CHUK 1062/4885LRRK2 3561/4885 |
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | HAVCR2, NR4A3, NR2C2 | CHEK1 4549/4885CHUK 2910/4885LRRK2 2992/4885 |
| US-20100144655-A1 | ORGANIC COMPOUNDS | OAT, MAVS, HAVCR2 | CHEK1 2545/4885CHUK 1548/4885LRRK2 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.